San Diego, California | April 13, 2026
Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI® (sparsentan), making it the first and only approved treatment for focal segmental glomerulosclerosis (FSGS). The approval marks a historic milestone in rare kidney disease treatment, enabling the use of FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older without nephrotic syndrome. This regulatory achievement significantly expands the drug’s reach beyond IgA nephropathy (IgAN) and positions it as a potential foundational therapy for more than 30,000 FSGS patients in the United States, with a broader addressable population exceeding 100,000 patients across kidney diseases.
FDA Approval Marks Breakthrough in Rare Kidney Disease Treatment
The FDA approval of FILSPARI represents a major advancement for patients suffering from FSGS, a rare and progressive kidney disorder characterized by protein leakage, inflammation, and scarring of the kidney’s filtration system. Historically, treatment options have been limited, often relying on off-label therapies such as corticosteroids, which carry significant long-term risks. FILSPARI introduces a targeted therapeutic approach, offering a clinically validated option aligned with KDIGO clinical practice guidelines for managing glomerular diseases. This milestone underscores the growing importance of precision therapies in nephrology, particularly for conditions with high unmet medical needs and limited treatment alternatives.
Phase 3 DUPLEX Study Demonstrates Strong Clinical Efficacy
The approval is supported by results from the Phase 3 DUPLEX clinical trial, the largest interventional study conducted in FSGS patients to date. The study demonstrated that patients treated with FILSPARI achieved a 46% reduction in proteinuria over 108 weeks, compared to 30% in patients treated with irbesartan, a commonly used standard therapy. In patients without nephrotic syndrome, FILSPARI showed even greater efficacy, achieving a 48% reduction in proteinuria versus 27% with irbesartan, with statistically significant results.
Advertisement
Additionally, the therapy demonstrated favorable kidney function outcomes, as measured by estimated glomerular filtration rate (eGFR), highlighting its potential to slow disease progression and preserve renal function. These findings establish FILSPARI as a clinically superior option in managing FSGS and improving long-term patient outcomes.
Real-Time Variant Tracker Enables Therapy Resistance Monitoring
A key innovation introduced by Personalis is the Real-Time Variant Tracker™, a first-of-its-kind feature that allows longitudinal tracking of therapy resistance mutations, such as ESR1, during MRD testing. This capability enables clinicians to monitor how tumors evolve over time and detect emerging resistance mechanisms, providing critical insights for adapting treatment strategies.
The platform’s ability to track mutations in real time represents a major advancement in dynamic cancer management, where treatment decisions can be continuously refined based on molecular changes. By combining real-world clinical data with analytical validation, the company has demonstrated that this feature can significantly enhance the clinical utility of MRD testing, supporting more informed and timely interventions.
Dual Mechanism of Action Enhances Kidney Protection
FILSPARI operates through a dual mechanism of action, targeting both endothelin type A receptors and angiotensin II receptors, which play critical roles in kidney inflammation and fibrosis. By simultaneously addressing these pathways, the drug helps reduce proteinuria, protect kidney structure, and limit disease progression. This innovative mechanism distinguishes FILSPARI from conventional therapies and aligns with the shift toward multi-targeted treatment strategies in chronic kidney diseases.
The drug demonstrated a manageable safety profile, comparable to existing therapies, although it requires monitoring due to potential risks such as hepatotoxicity and embryo-fetal toxicity, managed through a Risk Evaluation and Mitigation Strategy (REMS) program.
Expanding Access and Transforming Patient Care
With FDA approval, FILSPARI is now available for immediate prescription by nephrologists, supported by comprehensive patient programs such as Travere TotalCare®, which provides assistance with treatment access, insurance navigation, and ongoing patient support. The approval is expected to significantly improve clinical outcomes and quality of life for patients with FSGS, offering a new standard of care in a disease area that has long lacked effective therapies. The expansion of FILSPARI into FSGS also reinforces Travere’s leadership in rare disease therapeutics, highlighting its commitment to developing innovative solutions for underserved patient populations.
The FDA approval of FILSPARI marks a transformative moment in the treatment of focal segmental glomerulosclerosis, delivering the first approved therapy specifically targeting this rare and debilitating condition. With strong clinical efficacy, a novel dual-action mechanism, and broad patient applicability, FILSPARI is poised to redefine treatment standards in nephrology. This milestone underscores the critical role of regulatory innovation, clinical research, and precision medicine in addressing unmet needs in rare diseases and improving patient outcomes worldwide.
Source: Travere Therapeutics press release
